Literature DB >> 35363557

Re: "Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial" by Crippa et al.

Luis Vitetta1,2, Tomas Andersen2, Michelle Quezada2, Dave Rutolo2, Jeremy D Henson2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35363557      PMCID： PMC9070739          DOI： 10.1089/can.2022.0034

Source DB:  PubMed          Journal:  Cannabis Cannabinoid Res        ISSN： 2378-8763


× No keyword cloud information.
  13 in total

Review 1.  Modulatory role of the endocannabinoidome in the pathophysiology of the gastrointestinal tract.

Authors:  Jerome Lian; Ilaria Casari; Marco Falasca
Journal:  Pharmacol Res       Date:  2021-12-07       Impact factor: 7.658

2.  Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Authors:  José Alexandre S Crippa; Julia Cozar Pacheco; Antonio W Zuardi; Francisco S Guimarães; Alline Cristina Campos; Flávia de Lima Osório; Sonia Regina Loureiro; Rafael G Dos Santos; José Diogo S Souza; Juliana Mayumi Ushirohira; Rafael Rinaldi Ferreira; Karla Cristinne Mancini Costa; Davi Silveira Scomparin; Franciele Franco Scarante; Isabela Pires-Dos-Santos; Raphael Mechoulam; Flávio Kapczinski; Benedito A L Fonseca; Danillo L A Esposito; Afonso Dinis Costa Passos; Amaury Lelis Dal Fabbro; Fernando Bellissimo-Rodrigues; Eurico Arruda; Sandro Scarpelini; Maristela Haddad Andraus; Julio Cesar Nather Junior; Danilo Tadao Wada; Marcel Koenigkam-Santos; Antonio Carlos Santos; Geraldo Busatto Filho; Jaime E C Hallak
Journal:  Cannabis Cannabinoid Res       Date:  2021-10-07

Review 3.  Altered gut microbial metabolites could mediate the effects of risk factors in Covid-19.

Authors:  Jiezhong Chen; Sean Hall; Luis Vitetta
Journal:  Rev Med Virol       Date:  2021-01-13       Impact factor: 11.043

Review 4.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Gaps in predicting clinical doses for cannabinoids therapy: Overview of issues for pharmacokinetics and pharmacodynamics modelling.

Authors:  Zheng Liu; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2018-06-07       Impact factor: 4.335

Review 6.  The pharmacokinetics and the pharmacodynamics of cannabinoids.

Authors:  Catherine J Lucas; Peter Galettis; Jennifer Schneider
Journal:  Br J Clin Pharmacol       Date:  2018-08-07       Impact factor: 4.335

7.  Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses.

Authors:  Long Chi Nguyen; Dongbo Yang; Vlad Nicolaescu; Thomas J Best; Haley Gula; Divyasha Saxena; Jon D Gabbard; Shao-Nong Chen; Takashi Ohtsuki; John Brent Friesen; Nir Drayman; Adil Mohamed; Christopher Dann; Diane Silva; Lydia Robinson-Mailman; Andrea Valdespino; Letícia Stock; Eva Suárez; Krysten A Jones; Saara-Anne Azizi; Jennifer K Demarco; William E Severson; Charles D Anderson; James Michael Millis; Bryan C Dickinson; Savaş Tay; Scott A Oakes; Guido F Pauli; Kenneth E Palmer; David O Meltzer; Glenn Randall; Marsha Rich Rosner
Journal:  Sci Adv       Date:  2022-02-23       Impact factor: 14.957

Review 8.  Cannabinoid Delivery Systems for Pain and Inflammation Treatment.

Authors:  Natascia Bruni; Carlo Della Pepa; Simonetta Oliaro-Bosso; Enrica Pessione; Daniela Gastaldi; Franco Dosio
Journal:  Molecules       Date:  2018-09-27       Impact factor: 4.411

9.  Gut microbiome alterations and gut barrier dysfunction are associated with host immune homeostasis in COVID-19 patients.

Authors:  Zhonghan Sun; Zhi-Gang Song; Chenglin Liu; Shishang Tan; Shuchun Lin; Jiajun Zhu; Fa-Hui Dai; Jian Gao; Jia-Lei She; Zhendong Mei; Tao Lou; Jiao-Jiao Zheng; Yi Liu; Jiang He; Yuanting Zheng; Chen Ding; Feng Qian; Yan Zheng; Yan-Mei Chen
Journal:  BMC Med       Date:  2022-01-20       Impact factor: 8.775
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.